Fortgeschrittenes Nierenzellkarzinom: Nivolumab/Cabozantinib versus Sunitinib

Aktuelle Urol. 2022 Feb;53(1):16-18. doi: 10.1055/a-1559-4893. Epub 2022 Jan 25.NO ABSTRACTPMID:35078256 | DOI:10.1055/a-1559-4893

Source: Aktuelle Urologie - January 25, 2022 Category: Urology & Nephrology Source Type: research